Table 5 Mean change from baseline in CFT at 6 months

IVR 0.5 mg vs non-anti-VEGF

Type of RVO

  All trials

4

−216.86 (−279.01, −154.71)

<0.001

5.57

0.135

46.1%

  CRVO

2

−230.84 (−357.63, −104.06)

<0.001

3.03

0.082

67.0%

  BRVO

2

−190.05 (−243.33, −136.78)

<0.001

0.07

0.789

0.00%

Sample size

4

−216.86 (−279.01, −154.71)

<0.001

5.57

0.135

46.1%

  >100

2

−233.77 (−328.83, −138.72)

<0.001

4.49

0.034

77.7%

  <100

2

−175.95 (−277.40, −74.50)

<0.001

0.30

0.585

0.00%

Different non-anti-VEGF treatment

  All trials

4

−216.86 (−279.01, −154.71)

<0.001

5.57

0.135

46.1%

  Sham

3

−216.42 (−292.99, −139.85)

<0.001

5.56

0.062

64.0%

  Sham plus laser

1

−210.84 (−371.90, −49.79)

<0.001

-

IVR 0.5 mg vs IVR 0.3 mg

2

−12.26 (−55.60, 31.08)

0.579

0.06

0.812

0.00%

IVR 0.3 mg vs non-anti-VEGF

2

−218.97 (−303.31, −134.63)

<0.001

3.39

0.066

70.5%